Haemonetics Corporation (NYSE:HAE) Stock Has Consensus Price Target of $110.00 According to Analysts

Haemonetics Corporation (NYSE:HAE) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $110.00.

HAE has been the subject of several research reports. Mizuho raised their price target on shares of Haemonetics from $95.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Citigroup upped their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Raymond James Financial increased their target price on shares of Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. Finally, Robert W. Baird lifted their target price on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research note on Friday, August 21st.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of HAE. Nierenberg Investment Management Company LLC acquired a new stake in Haemonetics in the second quarter valued at approximately $1,971,000. Rice Hall James & Associates LLC bought a new stake in Haemonetics in the second quarter worth approximately $3,828,000. Renaissance Technologies LLC bought a new stake in Haemonetics in the first quarter worth approximately $2,435,000. Quantinno Capital Management LP increased its stake in shares of Haemonetics by 438.0% during the 1st quarter. Quantinno Capital Management LP now owns 30,708 shares of the medical instruments supplier’s stock worth $1,731,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Aurora Investment Counsel acquired a new position in shares of Haemonetics during the 2nd quarter worth $1,913,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Up 1.3%

NYSE:HAE opened at $119.84 on Tuesday. The business’s fifty day moving average price is $109.79 and its 200 day moving average price is $78.67. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 2.37 and a beta of 0.61. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. Haemonetics has a 1-year low of $49.00 and a 1-year high of $123.77.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The firm had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. During the same period last year, the company posted $1.10 EPS. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, sell-side analysts forecast that Haemonetics will post 5.29 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.